Skip to main content

Advertisement

SpringerLink
Log in

Psoriasis market

  • From the Analyst's Couch
  • Published:

From Nature Reviews Drug Discovery

View current issue Sign up to alerts

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1: Breakdown of use of various therapeutic modalities in patients with psoriasis depending on the disease severity.
Figure 2: 2008 sales of selected psoriasis drugs.

References

  1. Menter, A. et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. J. Am. Acad. Derm. 58, 826–850 (2008).

    Article  Google Scholar 

  2. Rozenblit, M. & Lebwohl, M. New biologics for psoriasis and psoriatic arthritis. Derm. Therapy. 22, 56–60 (2009).

    Article  Google Scholar 

  3. Reich, K. et al. Ustekinumab. Nature Rev. Drug Discov. 8, 355–356 (2009).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Irena Melnikova, Ph.D., is a Principal at TVM Capital, 101 Arch Street, Boston, Massachusetts 02110, USA. melnikova@tvm-capital.com,

    Irena Melnikova

Authors
  1. Irena Melnikova
    View author publications

    You can also search for this author in PubMed Google Scholar

Related links

Related links

FURTHER INFORMATION

Clinical trials.gov

The National Psoriasis Foundation

Rights and permissions

Reprints and permissions

About this article

Cite this article

Melnikova, I. Psoriasis market. Nat Rev Drug Discov 8, 767–768 (2009). https://doi.org/10.1038/nrd2996

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd2996

  • Springer Nature Limited

This article is cited by

Search

Navigation